Yakira Capital Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-155,177
Closed -$133K 187
2019
Q4
$133K Hold
155,177
0.04% 121
2019
Q3
$87K Hold
155,177
0.03% 130
2019
Q2
$81K Hold
155,177
0.02% 129
2019
Q1
$70K Hold
155,177
0.02% 109
2018
Q4
$74K Hold
155,177
0.02% 107
2018
Q3
$82K Hold
155,177
0.02% 122
2018
Q2
$78K Hold
155,177
0.02% 113
2018
Q1
$66K Hold
155,177
0.02% 116
2017
Q4
$59K Hold
155,177
0.02% 100
2017
Q3
$56K Hold
155,177
0.02% 108
2017
Q2
$59K Hold
155,177
0.02% 100
2017
Q1
$70K Hold
155,177
0.03% 93
2016
Q4
$59K Hold
155,177
0.03% 75
2016
Q3
$42K Hold
155,177
0.01% 75
2016
Q2
$37K Hold
155,177
0.01% 101
2016
Q1
$18K Hold
155,177
0.01% 111
2015
Q4
$17K Hold
155,177
﹤0.01% 115
2015
Q3
$30K Sell
155,177
-9,300
-6% -$3.16K 0.02% 118
2015
Q2
$115K Hold
164,477
0.06% 107
2015
Q1
$112K Hold
164,477
0.08% 76
2014
Q4
$130K Hold
164,477
0.1% 80
2014
Q3
$76K Hold
164,477
0.06% 89
2014
Q2
$82K Hold
164,477
0.06% 99
2014
Q1
$51K Hold
164,477
0.05% 78
2013
Q4
$56K Buy
+164,477
New +$199K 0.06% 84

Yakira Capital Management's GCVRZ Position: Q1 2020 in Review

Yakira Capital Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 155,177 shares — an estimated $133K sold.

Yakira Capital Management first reported a position in GCVRZ in Q4 2013 and held it in 25 quarters. The position peaked at $133K in Q4 2019. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.

  • Yakira Capital Management reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
  • Yakira Capital Management sold 155,177 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $133K.
  • Yakira Capital Management first reported a position in Sanofi Contingent Value Rights in Q4 2013 and held it in 25 quarters.
  • Yakira Capital Management's Sanofi Contingent Value Rights position peaked at $133K in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.

Based on Yakira Capital Management's 13F filing for Q1 2020, filed 14 May 2020.